Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Withdrawn2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

withdrawn267%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
withdrawnphase_1

Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents

NCT05013983
completedphase_3

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

NCT04904471
withdrawnphase_2

Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)

NCT04718467

Clinical Trials (3)

Showing 3 of 3 trials
NCT05013983Phase 1

Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents

Withdrawn
NCT04904471Phase 3

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

Completed
NCT04718467Phase 2

Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3